| |
BCa-1
|
BCa-2
|
|
N (%)
|
N (%)
|
OR (95% CI) a
|
|
Histology
|
|
Ductal
|
643,139 (72.8)
|
25,487 (70.2)
|
1.00
|
|
Lobular
|
73,112 (8.3)
|
3456 (9.5)
|
1.01 (0.97–1.05)
|
|
Mixed
|
82,546 (9.3)
|
3439 (9.5)
|
1.02 (0.98–1.06)
|
|
Others
|
85,084 (9.6)
|
3931 (10.8)
|
1.04 (1.00–1.08)
|
|
Tumor grade
|
|
Well differentiated
|
165,869 (18.8)
|
7817 (21.5)
|
1.00
|
|
Moderately differentiated
|
337,563 (38.2)
|
14,526 (40.0)
|
0.97 (0.94–1.00)
|
|
Poorly differentiated
|
277,729 (31.4)
|
9435 (26.0)
|
0.91 (0.88–0.94)
|
|
Undifferentiated
|
9863 (1.1)
|
266 (0.7)
|
0.86 (0.76–0.98)
|
|
Tumor size
|
|
0-2 cm
|
506,784 (57.3)
|
22,629 (62.3)
|
1.00
|
|
2-5 cm
|
260,786 (29.5)
|
9608 (26.5)
|
0.85 (0.83–0.87)
|
|
> 5 cm
|
66,236 (7.5)
|
1884 (5.2)
|
0.67 (0.64–0.71)
|
|
Tumor stage
|
|
Local
|
547,036 (61.9)
|
24,624 (67.8)
|
1.00
|
|
Regional
|
265,617 (30.1)
|
8815 (24.3)
|
0.86 (0.84–0.88)
|
|
Distant
|
57,578 (6.5)
|
2065 (5.7)
|
0.79 (0.75–0.83)
|
|
Molecular subtypesc
|
|
HR+/HER2-
|
205,424 (67.4)
|
11,106 (70.4)
|
1.00
|
|
HR+/HER2+
|
30,893 (10.1)
|
1283 (8.1)
|
0.93 (0.88–0.99)
|
|
HR−/HER2+
|
13,507 (4.4)
|
492 (3.1)
|
0.82 (0.75–0.90)
|
|
Triple negative
|
32,172 (10.6)
|
1481 (9.4)
|
1.00 (0.94–1.05)
|
| |
N (%)
|
N (%)
|
OR (95% CI) b
|
|
Surgery d
|
|
No
|
60,648 (7.8)
|
3712 (11.6)
|
1.00
|
|
Lumpectomy
|
404,612 (52.3)
|
17,372 (54.1)
|
0.75 (0.72–0.79)
|
|
Mastectomy
|
304,812 (39.4)
|
10,900 (33.9)
|
0.74 (0.71–0.78)
|
|
Chemotherapy
|
|
No/unknown
|
536,470 (60.7)
|
27,537 (75.8)
|
1.00
|
|
Yes
|
347,411 (39.3)
|
8776 (24.2)
|
0.84 (0.81–0.86)
|
|
Radiotherapy
|
|
No/unknown
|
462,215 (52.3)
|
21,631 (59.6)
|
1.00
|
|
Yes
|
421,666 (47.7)
|
14,682 (40.4)
|
0.83 (0.82–0.85)
|
|
Treatment modesd
|
|
Lumpectomy only
|
79,295 (10.3)
|
5149 (16.0)
|
1.00
|
|
Mastectomy only
|
138,766 (17.9)
|
6648 (20.7)
|
0.88 (0.85–0.92)
|
|
Chemo−/radio-therapy
|
27,038 (3.5)
|
1038 (3.2)
|
1.05 (0.97–1.13)
|
|
Lumpectomy plus chemo−/radio-therapy
|
325,317 (42.1)
|
12,223 (38.0)
|
0.79 (0.76–0.82)
|
|
Mastectomy plus chemo−/radio-therapy
|
166,046 (21.5)
|
4252 (13.2)
|
0.74 (0.71–0.78)
|
|
Otherse
|
36,829 (4.8)
|
2817 (8.8)
|
1.16 (1.10–1.23)
|
- NOTE. Patients with missing information on tumor stage (N = 14,459, 1.57%), tumor grade (N = 97,126, 10.56%), tumor size (N = 52,267, 5.68%), molecular types (N = 24,220, 7.6%) or surgery (N = 3362, 0.4%) were not included in the corresponding analysis
- Abbreviations: BCa-1 Breast cancer as the first malignancy, CI Confidence interval, HR Hormone-receptor, HER2 Human epidermal growth factor receptor 2, N Number; OR Odds ratio
- a The models were adjusted for age (continuous) and calendar period at diagnosis, race, cohabitation status, percentile of cost of living and high-school education in county of residence
- b The models were additionally adjusted for tumor stage, histology, tumor grade, ER status, PR status, and HER2 status
- c Information on HER2 status was available from 2010 onward, and thus the analysis was restricted to patients diagnosed thereafter
- d Information on surgery and therapy was available from 1998 onward, and thus the analysis was restricted to patients diagnosed thereafter
- e Others included surgery (no/unknown), chemotherapy (no/unknown), and radiotherapy (no/unknown)
